May 18, 2011
Paul E. Sax, M.D., is director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston.
Quick question: If there were one piece of information -- clinical or lab -- that you would use to determine the quality of care in an HIV program, what would it be? (Choose one.)
Maybe I'm being presumptuous here, but one of these -- virologic suppression -- completely blows the rest of them away. Sure, the others are worthwhile, but data linking them to improved outcomes for people with HIV are either pretty weak (adherence counseling, flu vaccine) or nonexistent (toxoplasmosis serology).
Even the use of PCP prophylaxis for CD4 < 200, which was highly effective and prolonged survival in the pre-ART era, doesn't come close to the benefits of effective ART. One paper even questions whether we need it, provided that the person is on fully suppressive HIV therapy.
The reason? Anything with "HIV" attached to it, you see, is privacy-protected information under Massachusetts Chapter 111, Section 70F, unless the patient provides written informed consent. No exceptions listed.
Which means that people with HIV can't participate in this quality improvement program -- in effect, are discriminated against -- due to a law that in the post HIPAA era should not even be necessary, since all medical information is now considered confidential.
The state law on HIV testing and privacy, by the way, dates back to when HIV was called "HTLV-III", and it's showing its age. Fortunately, revisions to it are in the works that allow for appropriate testing, clinical care, research, and quality improvement.
Paul Sax is Clinical Director of Infectious Diseases at Brigham and Women's Hospital. His blog HIV and ID Observations is part of Journal Watch, where he is Editor-in-Chief of Journal Watch AIDS Clinical Care.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.